Cerus Corp at Morgan Stanley Healthcare Conference Transcript
Well, thanks, everyone. My name is David Horn, and I would just point everyone to the relevant disclosures on our website around forward statements and things like that, that will potentially happen here. With me today is Obi Greenman, CEO of Cerus; and Kevin Green, CFO of Cerus. And so for people who may not be familiar with Cerus, Obi, can you just give us a quick high-level overview of the company?
Yes. But before that, we'll probably be making a number of forward-looking statements today, so I just want to refer you to our SEC filings, again, on the risk factors there. So Cerus is a company that's focused on enhancing the safety and availability of the blood supply, specifically for transfused blood components. And our technology takes advantage of the fact that transfused blood components, specifically red cells, platelets and plasma, don't have any functioning nucleic acid, DNA and RNA. And so by targeting the nucleic acid in a blood component, we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |